文献速递神经肿瘤

偶然发现脑膜瘤在分子分型系统中临床结局良好

Incidental meningiomas have favorable clinical outcomes across molecular classification systems.
PubMed 文献 · Neuro Oncol · 2026-01-01

该研究对238例连续偶然发现脑膜瘤进行序列MRI、IMPACT分组、靶向基因表达、DNA甲基化和拷贝数分析,发现多数为分子低风险,IMPACT分组可分层无治疗和无症状生存,支持多数偶然脑膜瘤监测、分子高风险者早期治疗。

要点

  • 偶然脑膜瘤多数分子低风险,临床结局优于非偶然脑膜瘤。
  • IMPACT分组可分层无治疗生存(P<.0001)和无症状生存(P=.0007)。
  • 高甲基化DNA分组者IMPACT评分更高(P=.0020),可考虑早期治疗。

核心结论

  • 偶然脑膜瘤在分子分型系统中多属低风险,临床结局良好。
  • 支持多数偶然脑膜瘤采取监测策略,分子高风险者早期治疗可能改善结局。

研究设计与样本

  • 单中心连续238例偶然脑膜瘤的序列MRI、IMPACT分组、靶向基因表达、DNA甲基化和拷贝数分析。

主要发现

  • 队列81%为女性,检测时中位年龄59岁,中位肿瘤体积3.83 cm³。
  • 15.5%出现症状,93.7%接受治疗(中位治疗时间1.06年),5%复发。
  • IMPACT分组可分层无治疗生存(P<.0001)和无症状生存(P=.0007)。
  • 高甲基化DNA甲基化组IMPACT评分更高(P=.0020)。
  • 偶然脑膜瘤具有独特拷贝数变异和基因表达模式,结局优于1434例非偶然脑膜瘤。

关键数值与推荐

  • IMPACT分组分层无治疗生存P<.0001,无症状生存P=.0007。
  • 高甲基化DNA甲基化组IMPACT评分更高P=.0020。

临床怎么用

  • 多数偶然发现脑膜瘤可采取保守监测。
  • 对分子高风险(如高甲基化组)病例可考虑早期治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical and radiographic models predict incidental meningioma growth, but their molecular architecture is unknown. METHODS: We analyzed serial magnetic resonance imaging, IMPACT groups (Incidental Meningioma: Prognostic Analysis Using Patient Comorbidity and MRI Tests), targeted gene expression, DNA methylation, and copy number (CNA) profiling of 238 consecutive incidental meningiomas from a single neurosurgical center. RESULTS: The cohort was 81% female, with a median age of 59 years at detection and median tumor volume of 3.83 cm³. Symptoms developed in 15.5%; 93.7% were treated (median time-to-treatment 1.06 years), with 5% recurrence. IMPACT groups stratified treatment-free (P < .0001) and symptom-free survival (P = .0007). Most meningiomas were molecularly low risk, although those from the hypermitotic DNA methylation group had higher IMPACT scores (P = .0020). Incidental meningiomas had distinct CNA and gene expression patterns and favorable outcomes compared to 1434 nonincidental meningiomas. CONCLUSIONS: These findings support surveillance for most incidental meningiomas, but early treatment may improve outcomes for molecularly higher-risk cases. Meningiomas are common, heterogeneous brain tumors that range in clinical presentation from benign to malignant. Many meningiomas are diagnosed “incidentally,” meaning that they do not initially cause symptoms and are found almost by accident during evaluation of unrelated medical conditions. This study investigates the natural history and biology of incidental meningiomas. Our data reveal that incidental meningiomas are enriched in molecular programs that are associated with favorable clinical outcomes in comparison to nonincidental, symptomatic meningiomas. These data support a general paradigm of conservative medical management for incidentally diagnosed meningiomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Nguyen MP, Mirchia K, Chen WC, et al. Incidental meningiomas have favorable clinical outcomes across molecular classification systems. Neuro Oncol. 2026. PMID: 41999202. doi:10.1093/neuonc/noag086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。